Prajmaline
Encyclopedia
Prajmaline is a class Ia antiarrhythmic agent
which has been available since the 1970’s. Class Ia drugs increase the time one action potential lasts in the heart. Prajmaline is a semi-synthetic propyl derivative of ajmaline
, with a higher bioavailability than its predecessor. It acts to stop arrhythmias of the heart through a frequency-dependent block of cardiac sodium channels.
Daily therapeutic dose is 40-80 mg.
Distribution half-life is 10 minutes.
Plasma protein binding is 60%.
Oral bioavailability is 80%.
Elimination half-life is 6 hours.
Volume of distribution is 4-5 L/kg.
Antiarrhythmic agent
Antiarrhythmic agents are a group of pharmaceuticals that are used to suppress abnormal rhythms of the heart , such as atrial fibrillation, atrial flutter, ventricular tachycardia, and ventricular fibrillation....
which has been available since the 1970’s. Class Ia drugs increase the time one action potential lasts in the heart. Prajmaline is a semi-synthetic propyl derivative of ajmaline
Ajmaline
Ajmaline is a class Ia antiarrhythmic agent. It is often used to bring out typical findings of ST elevations in patients suspected of having Brugada syndrome....
, with a higher bioavailability than its predecessor. It acts to stop arrhythmias of the heart through a frequency-dependent block of cardiac sodium channels.
Mechanism
Prajmaline causes a resting block in the heart. A resting block is the depression of a person’s Vmax after a resting period. This effect is seen more in the atrium than the ventricle. The effects of some Class I antiarrhythmics are only seen in a patient who has a normal heart rate (~1 Hz). This is due to the effect of a phenomenon called reverse use dependence. The higher the heart rate, the less effect Prajmaline will have.Uses
The drug Prajmaline has been used to treat a number of cardiac disorders. These include: coronary artery disease , angina, paroxysmal tachycardia and Wolff–Parkinson–White syndrome. Prajmaline has been indicated in the treatment of certain disorders where other antiarrhythmic drugs were not effective.Administration
Prajmaline can be administered orally, parenterally or intravenously. Three days after the last dose, a limited effect has been observed. Therefore it has been suggested that treatment of arrhythmias with Prajmaline must be continuous to see acceptable results.Pharmacokinetics
The main metabolites of Prajmaline are: 21-carboxyprajmaline and hydroxyprajmaline. Twenty percent of the drug is excreted in the urine unchanged.Daily therapeutic dose is 40-80 mg.
Distribution half-life is 10 minutes.
Plasma protein binding is 60%.
Oral bioavailability is 80%.
Elimination half-life is 6 hours.
Volume of distribution is 4-5 L/kg.